Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.cian.co | |
Market Cap | 46.29 Cr. | |
Enterprise Value(EV) | 86.57 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 0.81 | Trailing Twelve Months Ending 2023-03 |
Price-Earning Ratio (PE) | 22.81 | Trailing Twelve Months Ending 2023-03 |
Industry PE | 38.68 | Trailing Twelve Months Ending 2023-03 |
Book Value / Share | 18.98 | Trailing Twelve Months Ending 2023-03 |
Price to Book Value | 0.98 | Calculated using Price: 18.52 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 2.50 Cr. | 24,995,764 Shares |
FaceValue | 10 | |
About Cian Healthcare Ltd. | ||
The Company develops, manufactures and commercializes pharmaceutical products including sales, marketing, quality assurance, distribution, compliance and regulatory aspects under 12 therapeutic segments like Orthopaedics, Gynaecology, Paediatrics, Cardiac, Diabetic, Dermatology, Pain Management, Antibiotics, Neuro, Critical Care, Gastro-Intestinal and Nutraceuticals, along with 10 sales division focused on developing and growing its engagements in specialist and super specialist division. The company works under different business models like Brand Business, Export, Third Party Manufacturing and Government Supplies. The Company manufactures innovative products comprising of Tablets, Capsules, Liquid Orals, Ointments, Creams, Lotions, Gels and Sachet. The Company has special licence for manufacturing veterinary products for client like SAVAvet and Venky's. |
1 Day |
|
-1.46% |
1 Week |
|
-4.45% |
1 Month |
|
-16.28% |
3 Month |
|
-29.40% |
6 Month |
|
-54.20% |
1 Year |
|
+1.39% |
2 Year |
|
+9.28% |
5 Year |
|
|
10 Year |
|
4 years | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | -7.53 | 0.10 | -10.51 | 4.06 | |
Return on Capital Employed (%) | 3.00 | 6.99 | 0.46 | 7.41 | |
Return on Assets (%) | -2.42 | 0.03 | -3.42 | 1.24 |
Particulars | 5 years | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 58 | 58 | 55 | 57 | 56 | |
Non Curr. Liab. | 50 | 41 | 41 | 38 | 37 | |
Curr. Liab. | 48 | 58 | 69 | 65 | 71 | |
Minority Int. | ||||||
Equity & Liab. | 157 | 157 | 166 | 160 | 163 | |
Non Curr. Assets | 94 | 88 | 84 | 76 | 84 | |
Curr. Assets | 54 | 63 | 79 | 74 | 79 | |
Misc. Exp. not W/O | 8 | 5 | 3 | 10 | ||
Total Assets | 157 | 157 | 166 | 160 | 163 |
Particulars | 4 years | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Net Sales | 57 | 74 | 78 | 69 | |
Other Income | 1 | 0 | 1 | 1 | |
Total Income | 58 | 74 | 78 | 69 | |
Total Expenditure | -50 | -62 | -74 | -56 | |
PBIDT | 8 | 12 | 5 | 14 | |
Interest | -7 | -8 | -7 | -6 | |
Depreciation | -4 | -3 | -4 | -5 | |
Taxation | 0 | -1 | 0 | 0 | |
Exceptional Items | 0 | 0 | 0 | 0 | |
PAT | -4 | 0 | -6 | 2 | |
Minority Interest | |||||
Share Associate | |||||
Other Related Items | |||||
Consolidated Net Profit | -4 | 0 | -6 | 2 | |
Adjusted EPS | -2 | 0 | -2 | 1 |
Particulars | 4 years | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | -7 | 6 | 9 | 5 | |
Cash Fr. Inv. | -27 | 3 | 1 | 3 | |
Cash Fr. Finan. | 36 | -10 | -11 | -7 | |
Net Change | 1 | -1 | -1 | 0 | |
Cash & Cash Eqvt | 3 | 2 | 1 | 1 |
Thu, 30 Nov 2023
Corporate Insolvency Resolution Process (CIRP)-Updates - Corporate Insolvency Resolution Process (CIRP) Update on hearing before NCLT along with Order of Bench. |
Tue, 14 Nov 2023
Board Meeting Outcome for Outcome Of Meeting Of Board Of Director Dated 14Th November 2023 Outcome of Meeting of board of Director dated 14th November 2023 |
Tue, 14 Nov 2023
Declaration Of Financial Results For The Half Year Ended 30Th September 2023 Declaration of financial results for the half year ended on 30th September 2023 |
Thu, 30 Nov 2023 |
|
|
|
|
|